Human laboratory studies (Rush, Kelly, Hays, Baker & Wooten, 2002) and early case reports have prompted interest in modafinil, a novel wake promoting agent, recently approved for narcolepsy. Modafinil promotes wakefulness, vigilance and alertness and may have value in treating psychostimulant withdrawal symptoms such as hypersomnia, poor concentration and low mood. Case reports pointed to positive responses in both cocaine and amphetamine-dependent patients with no apparent over-stimulation or abuse (Comacho & Stein, 2002; Malcolm, Book, Moak, DeVane & Czepowicz, 2002). No medical risks in terms of blood pressure, pulse, temperature or electrocardiogram measures were identified in a placebo-controlled drug interaction study of modafinil and cocaine in seven subjects who received infusions of cocaine or modafinil (200 mg/day or 400 mg/day) over four days (Dackis, Lynch, Yu, Samaha et al., 2003).